Clinical Trial Update: CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca. [Phase 4]

View source ↗

Summary

This Phase 4 trial compares a stable dose SERETIDE inhaler with an adjustable maintenance dose SYMBICORT inhaler over one year in asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• SERETIDE Inhaler (salmeterol/fluticasone propionate)
• SYMBICORT Inhaler (budesonide/formoterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 4 | Status: COMPLETED